Document is current
Any future updates will be listed below
-
Authors
Copaescu, Ana M. https://orcid.org/0000-0002-9183-5032
Graham, Francois
Nadon, Nathalie
Gagnon, Rémi
Robitaille, Arnaud
Badawy, Mohamed
Claveau, David
Roches, Anne Des
Paradis, Jean
Vincent, Matthieu
Bégin, Philippe
-
Funding
Funding for this research was provided by:
Fonds de Recherche du Québec - Santé (281662)
Melbourne Research, University of Melbourne
Fondation de l'Hôpital Général de Montréal
- License Information
-
More Information
Article History
Received: 22 July 2022
Accepted: 14 January 2023
First Online: 29 January 2023
Declarations
:
: This study was approved by the CHUM ethics committee. The CÉR (Comité d’éthique de la recherche) CHUM number is 18.361.
: Written informed consent for study analysis and publication was obtained from the interviewed participants.
: RG—Investigator for Boehringer Ingelheim, Astra Zeneca, Merk, GSK, Novartis, Stallergene, DBV, Sanofi, Green Cross, Advisor committee for Novartis, Aralez, Mylan, ALK, Presenter for Merk, Pfizer, Astram Aralez, Pediapharm, Novartis. MV—member of Ezdrips (non-profit organization). PB–PB received research grants from Novartis, Sanofi, Regeneron and DBV Technologies and personal fees from Novartis, Aralez, Sanofi-Genzyme, Bausch Health, ALK, Astra-Zeneca, Valeo and Pfizer, unrelated to this work. AC, FG, NN, AR, MB, DC, AD, JP—No conflict of interest.
